Experience of Using Bedaquiline in the Multimodality Therapy of Tuberculosis Patients With Concurrent Hiv Infection

Balasanyants, G. S.

doi:10.21292/2075-1230-2017-95-9-49-54

Cited by 10 publications

(2 citation statements)

References 1 publication

(1 reference statement)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… The efficacy of the TB treatment with the use of bedaquiline by the end of 24–26 weeks of therapy. Borisov et al [ 22 ], Morozova et al [ 23 ], Balasanyantzh [ 24 ], Lepshina et al [ 26 ], Konovalova et al [ 27 ], Kondakova et al [ 28 ], Tihonova et al [ 29 ], Borisov et al [ 30 ], Golubchikov et al [ 31 ], Danilova et al [ 32 ], Danilova et al [ 32 ], Stavickaya et al [ 33 ], Yablonskiy et al [ 35 ], Starshinova et al [ 36 ], Morozova et al [ 37 ]). …”

Section: Figurementioning

confidence: 99%

Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation

Старшинова

Dovgalyk

Belyaeva³

et al. 2022

Antibiotics

View full text Add to dashboard Cite

In the conditions of the continued growth of multiple- and extensive drug-resistant tuberculosis, use of the new highly effective anti-tuberculosis drugs in this patient category is of great relevance. The aim of the study was determination the efficacy of treatment in patients with multidrug- and extensive drug-resistant tuberculosis using bedaquiline based on studies published in the Russian Federation. Materials and methods: The authors analyzed data published in studies from 2014 to 2022; 41 publications were included in total and 17 articles corresponded to the study design. The results of treatment of 1404 tuberculosis patients with MDR/XDR TB were described. Bedaquiline was used according to the standard scheme with a description of the treatment results after 24–26 weeks. Treatment efficacy was estimated according to accepted criteria. Results of the study: The analysis showed that the treatment efficacy on conversion was achieved in 79.5% of cases (95% Cl 76.5–82.3), and recovery was observed in 82.0% of cases (95% Cl 78.6–85.1). Departure from the therapy was observed in rare cases (9.8%; 95% Cl 7.9–12.2). Deaths were recorded in 6.5% of cases (95% Cl 4.9–8.3), which were associated with the severe disease and concomitant pathology in 74.3%. The development of adverse events was noted in half of the patients (55.7%); however, bedaquiline cancellation occurred in a few cases (7.0%; 95% Cl 3.0–13.0). From analyzing data in patients with MDR and XDR TB, the efficacy of treatment was 89.9% (95% Cl 85.9–93.2) and 71.9% (95% Cl 66.2–77.1), respectively. Conclusion: Use of bedaquiline in treatment makes it possible to achieve recovery of patients with MDR/XDR TB in 82.0% of cases with patients dropping out of treatment in 9.8%. At the same time, in patients with MDR TB, recovery was achieved in 89.9% of cases, while in patients with XDR TB, 71.9% of cases recovered.

show abstract

Section: Figurementioning

confidence: 99%

Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation

Старшинова

Dovgalyk

Belyaeva³

et al. 2022

Antibiotics

View full text Add to dashboard Cite

show abstract

“…лечения/профилактики оппортунистических инфекций [1,3,9,16]. Приводим случай эффективного лечения туберкулеза множественных локализаций с МЛУ у ВИЧ-позитивного мультиморбидного пациента.…”

Section: туберкулёз и болезни лёгкихunclassified

Efcacy and safety of combination therapy with bedaquiline in a multimorbid HIV positive patient with multiple drug resistant tuberculosis

Жукова

Kulchavenya

2022

Tuberk. bolezni lëgk.

View full text Add to dashboard Cite

The article describes a clinical observation of the eﬀective treatment of a multimorbid HIV positive patient with multiple drug resistant tuberculosis. It demonstrates modern approaches to treatment and optimal chemotherapy regimens containing bedaquiline. In the treatment of patients with a combination of chronic infectious diseases (tuberculosis, HIV infection, parenteral hepatitis) and oncological pathology (kidney cancer), interdepartmental interaction of specialists (phthisiologists, infectious disease specialists, and oncologists) is needed in order to compile successful treatment regimens taking into account multiple comorbidities and the risk of adverse reactions to drug combinations and choose the right time to perform a successful surgery.

show abstract

The incidence of QT interval prolongation in patients receiving antituberculous therapy

Bykova¹,

Chashkina²,

Serova³

et al. 2019

Kardiol. serdechno-sosud. khir.

View full text Add to dashboard Cite

Experience of Using Bedaquiline in the Multimodality Therapy of Tuberculosis Patients With Concurrent Hiv Infection

Cited by 10 publications

References 1 publication

Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation

Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation

Efcacy and safety of combination therapy with bedaquiline in a multimorbid HIV positive patient with multiple drug resistant tuberculosis

The incidence of QT interval prolongation in patients receiving antituberculous therapy

Contact Info

Product

Resources

About